276880-88-7

Basic information

• Product Name: (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
• CAS NO: 276880-88-7
• Molecular Formula: C₂₇H₃₁NO₁₁
• Molecular Weight: 545.5351
• Mol File: 276880-88-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 828.7°C at 760 mmHg
• Flash Point: 455°C
• Density: 1.61g/cm³
• Vapor Pressure: 4.26E-29mmHg at 25°C
• Refractive Index: 1.716
• CAS DataBase Reference: (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside(276880-88-7)
• EPA Substance Registry System: (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside(276880-88-7)

Safety Data

• Hazardous Substances Data: 276880-88-7(Hazardous Substances Data)

Upstream product

• 23214-92-8 doxorubicin 

Downstream Products

• 210837-88-0 13-dihydroadriamycinone 
• 141975-30-6 doxorubicinol aglycone 

Relevant articles and documents

Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism

Doxorubicin (DOX) and daunorubicin (DAUN) are anthracycline anticancer agents; however, considerable interpatient variability exists in their pharmacokinetics. This interpatient variability is attributed in part to altered metabolism by nonsynonymous sing

Anthracycline glycoside compositions, their use and preparation

Anthracycline glycoside antibiotics are complexed with cardiolipin and then encapsulated in liposomes to reduce mammalian cardiac tissue uptake of the anthracycline glycoside and to thereby reduce the deleterious effect of such cardiac tissue uptake. The invention is directed to the composition, preparation and use of the encapsulated complex of anthracycline glycoside.